95PEvaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study

ConclusionsAR splice variants and mutations were absent/rare in treatment na ïve tumor samples from men with castrate-sensitive prostate cancers. The DRD+ cohort appears to show poorer rPFS outcome in AAP treated men.Clinical trial identificationNCT01715285.Editorial acknowledgementShweta Pitre, MPharm, ISMPP CMPP ™ (SIRO Clinpharm Pvt. Ltd., India) provided writing assistance and Namit Ghildyal, PhD (Janssen Global Services, LLC) provided additional editorial support.Legal entity responsible for the studyJanssen Research and Development, LLC.FundingJanssen Research and Development, LLC.DisclosureK.N. Chi: Research grant/Funding (self): Janssen Pharmaceuticals, Astellas Pharma, Amgen, Bayer, Novartis, Sanofi, Exelixis, Tokai Pharmaceuticals, Oncogenex, Teva; Advisory/Consultancy: ESSA, Astellas Pharma, Janssen Pharmaceuticals, Sanofi, Lilly/ImClone, Amgen, Bayer, Takeda Pharmaceuticals; Honoraria (self): Sanofi, Janssen Pharmaceuticals, Astellas Pharma. S. Thomas: Shareholder/Stockholder/Stock options, Full/Part-time employment: Janssen Research& Development. M. Gormley: Shareholder/Stockholder/Stock options, Full/Part-time employment: Janssen Research& Development. D. Shen: Shareholder/Stockholder/Stock options, Full/Part-time employment: Janssen Research& Development. S. Joshi: Full/Part-time employment: Janssen Research& Development. N. Tran: Shareholder/Stockholder/Stock options, Full/Part-time employment: Janssen Research& Development. M. Smith: Sh...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research